POM-V Prescription Required

Draxxin Plus 100 mg/ml + 120 mg/ml Solution for Injection for Cattle

Active ingredients: Ketoprofen, Tulathromycin

Form

Injection

Species

Cattle

Manufacturer

Zoetis Belgium S.A.

VMD MA No.

60021/3060

What it's used for

For the treatment of bovine respiratory disease (BRD) caused by haemolytica and of associated clinical signs of inflammation or pyrexia.

Full indications, dosage and side effects ↓

View official SPC (PDF)

The prescription itself has a price. See what practices near you charge for a consultation and the written prescription fee.

Paying less for Ketoprofen + Tulathromycin

1

Ask your vet for a written prescription

They must provide one on request. Under the CMA Order the fee is capped at £21 from 2027.
2

Fill it at a registered online retailer

The CMA found online pharmacies 50–60% cheaper than practice dispensing on common medicines — typically £200–£300 a year.

Your prescription rights → VMD register of retailers →

Prescription required

Your vet must provide a written prescription on request. You can then purchase from any licensed online retailer.

Clinical information

Draxxin Plus 100 mg/ml + 120 mg/ml Solution for Injection for Cattle — SPC Details

Source: VMD Summary of Product Characteristics (SPC). Last updated 27 Mar 2026.

For the treatment of bovine respiratory disease (BRD) caused by
haemolytica and
of associated clinical signs of inflammation or pyrexia.

A single subcutaneous injection of 2.5 mg tulathromycin/kg bodyweight and
3 mg ketoprofen/kg bodyweight (equivalent to 1 ml/40 kg bodyweight). For
treatment of cattle over 400 kg bodyweight, divide the dose so that no more
than 10 ml are injected at one site.
To ensure correct dosage bodyweight should be determined as accurately as
possible to avoid underdosing.
For any respiratory disease, it is recommended to treat animals in the early
stages of the disease and to evaluate the response to treatment within
48 hours after injection. If clinical signs of respiratory disease persist or
increase, or if relapse occurs, treatment should be changed, using another
antibiotic, and continued until clinical signs have resolved.
If there is persistent elevated body temperature 24 hours after treatment
initiation, the responsible veterinarian must evaluate the necessity of further
anti-pyretic treatment.
The stopper may be safely punctured up to 20 times. When treating groups of
animals in one run, use a draw-off needle that has been placed in the vial
stopper or an automatic syringe to avoid excessive broaching of the stopper.
The draw-off needle should be removed after treatment.

Do not use in cases of hypersensitivity to the active substances or to any of
the excipients.
Do not use simultaneously with other macrolides or lincosamides (see section
3.4).
Do not administer to animals suffering from gastrointestinal lesions,
haemorrhagic diathesis, blood dyscrasia or hepatic, renal or cardiac
conditions.

Cattle:
Very common
(>1 animal / 10 animals treated):
injection site pain
injection site swelling
1,2
injection site reaction
injection site oedema
injection site fibrosis
injection site haemorrhage
Very rare
(<1 animal / 10,000 animals
treated, including isolated
reports):
digestive tract disorder
renal disorder
hypersensitivity reactions (e.g.
anaphylaxis, dyspnoea, collapse)
1
May persist for up to 32 days after injection.
Pathomorphological injection site reactions are present for approximately
32 days after injection.
In case of such an allergic or anaphylactic reaction, appropriate symptomatic
treatment should be administered immediately.
Reporting adverse events is important. It allows continuous safety monitoring
of a veterinary medicinal product. Reports should be sent, preferably via a
veterinarian, to either the marketing authorisation holder or its local
representative or the national competent authority via the national reporting
system. See also section 16 of the package leaflet for respective contact
details.

Cross resistance occurs with other macrolides. Do not administer
simultaneously with antimicrobials with a similar mode of action such as other
macrolides or lincosamides.

This veterinary medicinal product does not contain any antimicrobial
preservative.
Special precautions for safe use in the target species:
Use of the veterinary medicinal product should be based on identification and
susceptibility testing of the target pathogen(s). If this is not possible, therapy
should be based on epidemiological information and knowledge of
susceptibility of the target bacteria at farm level, or at local/regional level.
Use of the veterinary medicinal product should be in accordance with official,
national and regional antimicrobial policies.
Use of the veterinary medicinal product deviating from the instructions given in
the SPC may increase the prevalence of bacteria resistant to tulathromycin
and may decrease the effectiveness of treatment with other macrolides,
lincosamides and group B streptogramins due to the potential for cross
resistance (MLSB resistance).
Since many NSAIDs possess the potential to induce gastrointestinal
ulceration, especially in aged cattle and young calves, concomitant use of the
veterinary medicinal product with other anti-inflammatory drugs (NSAIDs) or
steroidal anti-inflammatory drugs (e.g., corticosteroids) should be avoided
within the first 24 hours of treatment. Afterwards concurrent treatment with
NSAIDs and steroidal anti-inflammatory drugs should be closely monitored.
The use of the veterinary medicinal product (that contains ketoprofen) in aged
animals or animals less than 6 weeks should be based on a benefit/risk
assessment of the responsible veterinarian.
Avoid use in dehydrated, hypovolaemic or hypotensive animals which require
parenteral rehydration, as there may be a potential risk of renal toxicity.
Intra-arterial and intra-venous injection should be avoided.
Special precautions to be taken by the person administering the veterinary
medicinal product to animals:
•
People with known hypersensitivity to tulathromycin, ketoprofen, or to non-
steroidal anti-inflammatory drugs (NSAIDs) should avoid contact with the
veterinary medicinal product. In case of accidental spillage onto skin, wash
the skin immediately with soap and water.
•
exposure and self-injection. Take care to avoid skin contact and accidental
self-injection. In case of accidental self-injection, seek medical advice
immediately and show the package leaflet or the label to the physician.
•
unborn child. Pregnant women, women intending to conceive and men
planning to have children should use extreme caution while handling this
veterinary medicinal product.
•
the eyes. In case of accidental eye exposure, flush the eyes immediately
with clean water. If irritation persists, seek medical advice and show the
package leaflet to the physician.
•
Special precautions for the protection of the environment:
Not applicable.

interaction
Do not use concurrently with other diuretics, nephrotoxic veterinary medicinal
products or anticoagulants.

Do not freeze.

Meat and offal: 50 days.
Not authorised for use in cattle producing milk for human consumption.
Do not use in pregnant animals, which are intended to produce milk for human
consumption, within 2 months of expected parturition.
4.

This information is sourced from the official Summary of Product Characteristics (SPC) published by the Veterinary Medicines Directorate (VMD). It is provided for informational purposes only and does not replace professional veterinary advice. Always consult your vet before administering any medication.